Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced breast cancer.
Breast Cancer
DRUG: Navelbine|DRUG: Docetaxel
pCR, Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery., Through study completion, an average of 1 year
DFS, Disease-free Survival, Following surgery until Year 3|DDFS, Distance Disease-free Survival, Following surgery until Year 3|ORR, Objective Response Rate, Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced breast cancer.